Experts voted 13-0 that a HPV test was safe and effective as first step in cervical cancer screening.
A new clinical study has found that erlotinib has promising potential to improve treatment for cervical cancer.
Research has revealed that women with advanced cervical cancer live about 4 months longer with the combined use of bevacizumab and chemotherapy compared with chemotherapy alone.
Panel could recommend HPV test as a woman's new first option for cervical cancer screening.
Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|